Viridian Therapeutics, Inc.\DE (VRDN) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
the bull case· 3
4
funds on file reporting a position in the company
n-portas of Jun 30 '2611
disclosed supplier and customer ties in SEC filings
sec filingsedgar30
managers whose positions concentrate most of the reported value
13fJun 30 '26the bear case· 3
0.67%
largest fund weight on file within the reported fund universe
n-portJun 30 '267 of 8
recent reports with moves coming in under options implied ranges
earnings historyimplied vs realized2 of 24
largest reporting managers who reduced their stake in the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 9 '26 report. Not a forecast, not advice.
High 22.11 at 10:45 am ET, low 21.84 at 12:15 pm ET.
Viridian Therapeutics, Inc.\DE
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Of the 6 companies Viridian Therapeutics, Inc.\DE moves with most closely, none share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
tall tick = annual report · 1 on record
217 managers report a position worth $2.5B between them, and 30 of them hold 80% of it.
VRDN (Viridian Therapeutics, Inc.\DE) has 6 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.